Objective: To investigate the effects of in vitro Myo-inositol supplementation of cryopreserved human semen on the post-thaw sperm quality. Design: A randomized controlled clinical trial (RCT).
Introduction
e. Addition of myoinositol: After estimation of sperm motion kinetics, each sample was divided into 2 identical aliquots; one aliquot (Myo aliquot) was supplied with 2 mg/ ml myo-inositol (20 µl myo-inositol stock solution for each 1 ml of semen), the other aliquot (control aliquot) was left as it is. Both aliquots were incubated for 20 minutes (Rubino et al., 2015). f. Sperm cryopreservation: Both aliquots (Myo and control) were cryopreserved as follows: Sperm freezing media (Life global, Canada) was brought to room temperature at least 1 hour prior to cryopreservation. . This cryoprotectant was added dropwise to each aliquot ensuring through mixing after each drop, reaching a final dilution of 1:1. Each aliquot was then loaded into a straw labelled with the patient name and aliquot type (CBS High Security sperm straw, Cryo Bio System, France). Straws were suspended in liquid nitrogen vapor (10 cm above the level of liquid nitrogen at -80°C) for 15 minutes, before being plunged into liquid nitrogen (-196°C) and stored . g. Sperm thawing: After one week duration, the aliquots were brought out of liquid nitrogen to a temperature of 37° C to be thawed. Figures 1, 2) . 
Pre-freezing Vs post-thawing semen parameters and sperm motion kinetics among group (A) participants:
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Conclusion:
In vitro myoinositol supplementation of human sperm prior to cryopreservation resulted in a highly significant increase in cryosurvival rate among abnormal semen samples, and an increase in cryosurvival rate among normozoopermic samples that failed to reach a statistical significant difference. These findings may pave the way to include myoinositol in the manufacture of human sperm cryopreservation media. 
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